Summary of Progyny FY Conference Call (March 11, 2026) Company Overview - **Company**: Progyny (NasdaqGS: PGNY) - **Industry**: Fertility Benefits and Assisted Reproductive Technology Key Points Financial Performance - **4Q Performance**: Progyny exceeded guidance with a growth of approximately 20% in 2025, excluding one customer [1] - **Client Retention**: The company achieved a 99% client retention rate, with about 30% of clients expanding their benefits [2] - **Revenue Guidance**: The company has guided for a revenue growth of about 7% for the year, aligned with membership growth [34] Membership and Utilization - **Membership Estimate**: The estimated number of lives for 2026 was revised to 7.2 million, attributed to administrative updates rather than layoffs or macroeconomic factors [3] - **Utilization Rate**: The historical utilization rate has been consistent, ending last year at 1.04%. The company expects to remain within the low to middle of its historical utilization range for the current year [8] - **Impact of Macroeconomic Factors**: Utilization is primarily driven by the biological need for fertility assistance rather than macroeconomic conditions, such as tax refunds [10][11] Competitive Landscape - **Market Position**: Progyny competes more with managed care organizations (MCOs) that offer fertility benefits rather than standalone competitors. The company maintains a high win rate when clients decide to add fertility benefits [13][17] - **MCO Engagement**: MCOs have not become more aggressive in the fertility space due to lack of financial incentives, as they do not profit from increased utilization of fertility benefits [18][19] Product Expansion and Opportunities - **Client Expansion**: 30% of clients added to their offerings, including cycles and new products like menopause and postpartum support [20][22] - **Fully Insured Market**: Progyny is expanding into the fully insured market, addressing the needs of small employers who typically lack access to fertility benefits [24][25] - **Sales Cycle**: The sales cycle for fully insured buyers aligns with traditional cycles, with renewals generally occurring in the fourth quarter [28] Risk Management - **Contract Duration**: Fully insured buyers operate on annual contracts, allowing for premium adjustments based on experience [31] - **Utilization Risk**: Initial utilization risk exists with smaller populations, but as the risk pool grows, it will be managed similarly to self-insured populations [32] Future Outlook - **Growth Expectations**: The company expects to add approximately 1 million lives annually, with potential incremental contributions from new products [42] - **Long-term Margin Opportunities**: Future margin expansion is anticipated as investments taper off and operational efficiencies improve, particularly through AI and care management enhancements [39][40] Additional Insights - **Pipeline Status**: The current pipeline is primarily carryover from previous years, with positive expectations for the upcoming sales season [41] - **Market Positioning**: Progyny is well-positioned to expand its addressable market and maintain a competitive edge over standalone competitors and MCOs [42] This summary encapsulates the key insights and data points from the Progyny FY Conference Call, highlighting the company's performance, market dynamics, and future strategies.

As filed with the Securities and Exchange Commission on March 2, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEWGENIVF GROUP LIMITED (Exact name of registrant as specified in its charter) British Virgin Islands 8090 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Win ...

As filed with the U.S. Securities and Exchange Commission on February 2, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878- ...

Company Overview - INVO Fertility, Inc. is a healthcare fertility company focused on establishing, acquiring, and operating fertility clinics and related technologies [3] - The company operates two INVO Centers and one IVF clinic in the United States, and it sells the INVOcell medical device to third-party fertility clinics [3] - INVOcell is a proprietary medical device that allows fertilization and early embryo development to occur in vivo within the woman's body, offering a more intimate and affordable experience compared to traditional ART treatments [3] Upcoming Event - INVO Fertility will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026, at 3:00 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via provided links, with a replay available afterward [2]

As filed with the U.S. Securities and Exchange Commission on December 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INVO FERTILITY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Identification Number) 5582 Broadcast Court Sarasota, Florida, 34240 (978) 878 ...

Core Viewpoint - INVO Fertility, Inc. has signed a definitive purchase agreement to acquire Family Beginnings, P.C., marking a significant step in its strategy to expand its fertility care centers across the United States [1][2]. Group 1: Acquisition Details - The purchase agreement follows the announcement made on November 27, 2025, regarding the intent to acquire Family Beginnings [2]. - Family Beginnings generated approximately $1.2 million in revenue and $0.2 million in net income for the 12-month period ending September 30, 2025 [2]. - The total purchase price for the acquisition is $750,000, with $350,000 to be paid in cash at closing and $400,000 in preferred stock [4]. Group 2: Strategic Importance - The acquisition aligns with INVO's mission to enhance access to advanced fertility care and expand its operational footprint [3]. - Family Beginnings is recognized for its strong clinical reputation and offers a comprehensive range of reproductive services, including IVF and fertility preservation [3]. Group 3: Leadership and Integration - Dr. James Donahue will continue to lead Family Beginnings under a three-year agreement following the acquisition [4]. - The integration of Family Beginnings into INVO's operations is anticipated to build upon the existing foundation and further grow the practice in the local market [3].

Core Insights - INVO Fertility reported a strong financial performance in Q3 2025, with total revenue increasing by 23% year-over-year to $1,757,094, driven by higher patient volumes and enhanced marketing efforts [5][4] - The company achieved 18% organic growth across its clinics, attributed to increased patient flow and expanded telehealth capabilities [5][4] - The recent policy updates allowing employers to offer standalone infertility benefits are expected to further enhance access to IVF treatments, contributing to industry growth [5][4] Financial Highlights - Total revenue for Q3 2025 was $1,757,094, up from $1,433,151 in Q3 2024, marking a 23% increase [5] - Consolidated clinic revenue increased by 21% to $1,722,223 compared to $1,418,011 in the previous year [5] - The net loss for the quarter was $(2.6) million, compared to $(1.6) million in Q3 2024 [5] Operational and Strategic Highlights - The company is focused on strengthening organic performance and pursuing acquisition opportunities, with a pipeline of target clinics for potential acquisition [4] - INVOcell device revenue grew by 130% year-over-year, reflecting successful expansion initiatives and improved pricing strategies [5][4] - Operational efficiencies are being pursued through partnerships, such as with Heidi Health for AI-powered solutions [5][6] Management Commentary - The CEO emphasized the importance of organic growth and acquisition strategies in driving the company's mission to enhance patient access to fertility services [4] - The company is committed to operational efficiency to achieve profitability while expanding its services [6]

As filed with the Securities and Exchange Commission on October 10, 2025 Registration No. 333-290284 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Amendment No. 1 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEWGENIVF GROUP LIMITED (Exact name of registrant as specified in its charter) British Virgin Islands 8090 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Wing Fung Alfre ...

Core Insights - INVO Fertility, Inc. will participate in the Lytham Partners Fall 2025 Investor Conference, hosting a webcast presentation and one-on-one meetings with investors on September 30, 2025 [1][2][3] Company Overview - INVO Fertility is a healthcare services company focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [4] - The company's primary strategy includes building and operating "INVO Centers" that offer the intravaginal culture (IVC) procedure using the proprietary INVOcell medical device, which allows fertilization and early embryo development to occur in vivo within the woman's body [4] - INVO Fertility currently operates two INVO Centers and one IVF clinic in the United States, and it also sells and distributes the INVOcell device to third-party fertility clinics [4] - The IVC procedure is designed to provide a more connected, intimate, and affordable experience compared to traditional ART treatments, potentially delivering comparable results at a lower cost than traditional IVF [4]

As filed with the Securities and Exchange Commission on September 18, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEWGENIVF GROUP LIMITED (Exact name of registrant as specified in its charter) British Virgin Islands 8090 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number ...